A Randomized, Double-blind, Placebo-controlled Phase 1 Single and Multiple-Dose Pharmacokinetic First-in-Human Study of AV-001 in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 24 Jun 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AV 001-Vasomune Therapeutics (Primary)
Indications Adult respiratory distress syndrome; SARS-CoV-2 acute respiratory disease
Focus Adverse reactions; First in man
Sponsors Vasomune Therapeutics

22 May 2024 Results assessing safety and pharmacokinetics of AV001 in Healthy Subjects for the Treatment of Acute Respiratory Distress Syndrome presented at the 120th International Conference of the American Thoracic Society
06 May 2024 According to a Vasomune Therapeutics media release, data from this study will be presented at 2024 American Thoracic Society (ATS) International Conference
25 Mar 2021 Top-line results presented in a Vasomune Therapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com